Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HF 8 versus AMINOSYN RF 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HF 8 versus AMINOSYN RF 5 2.
AMINOSYN-HF 8% vs AMINOSYN-RF 5.2%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 mL to 1000 mL/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
None Documented
None Documented
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes.
Renal: >90% as amino acids and metabolites; fecal: <5%.
Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution